Entrada Therapeutics (NASDAQ:TRDA) CFO Kory James Wentworth Sells 11,388 Shares

Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth sold 11,388 shares of Entrada Therapeutics stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $13.02, for a total transaction of $148,271.76. Following the transaction, the chief financial officer owned 121,510 shares of the company’s stock, valued at $1,582,060.20. The trade was a 8.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Kory James Wentworth also recently made the following trade(s):

• On Monday, March 9th, Kory James Wentworth sold 5,089 shares of Entrada Therapeutics stock. The shares were sold at an average price of $13.00, for a total value of $66,157.00.
• On Wednesday, March 4th, Kory James Wentworth sold 7,988 shares of Entrada Therapeutics stock. The shares were sold at an average price of $12.25, for a total value of $97,853.00.

Entrada Therapeutics Stock Up 2.3%

Shares of NASDAQ TRDA traded up $0.30 during trading on Wednesday, reaching $13.50. The company had a trading volume of 210,880 shares, compared to its average volume of 236,376. Entrada Therapeutics, Inc. has a 12-month low of $4.93 and a 12-month high of $13.66. The business’s 50-day moving average is $11.16 and its 200 day moving average is $8.83. The stock has a market cap of $516.78 million, a PE ratio of -3.90 and a beta of -0.12.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.94) EPS for the quarter, beating the consensus estimate of ($1.32) by $0.38. The company had revenue of $1.30 million for the quarter, compared to the consensus estimate of $7.41 million. Entrada Therapeutics had a negative net margin of 565.48% and a negative return on equity of 39.83%. On average, analysts anticipate that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current year.

Analysts Set New Price Targets

TRDA has been the topic of several analyst reports. Guggenheim raised Entrada Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 11th. Weiss Ratings reissued a “sell (d)” rating on shares of Entrada Therapeutics in a report on Monday, December 29th. Wall Street Zen raised Entrada Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Entrada Therapeutics in a research report on Wednesday, February 18th. Finally, Oppenheimer initiated coverage on Entrada Therapeutics in a report on Wednesday, January 28th. They issued an “outperform” rating and a $21.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $18.50.

Hedge Funds Weigh In On Entrada Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of TRDA. Russell Investments Group Ltd. lifted its holdings in Entrada Therapeutics by 72.7% in the third quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock valued at $51,000 after acquiring an additional 3,707 shares during the period. State of Wyoming grew its stake in shares of Entrada Therapeutics by 130.9% during the 2nd quarter. State of Wyoming now owns 7,575 shares of the company’s stock valued at $51,000 after purchasing an additional 4,295 shares during the period. AXQ Capital LP purchased a new stake in shares of Entrada Therapeutics during the 3rd quarter valued at about $67,000. Occudo Quantitative Strategies LP bought a new position in shares of Entrada Therapeutics in the 2nd quarter worth approximately $68,000. Finally, Inscription Capital LLC purchased a new position in shares of Entrada Therapeutics in the third quarter worth approximately $69,000. 86.39% of the stock is currently owned by hedge funds and other institutional investors.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.